Log In
BCIQ
Print this Print this
 

AFM22

  Manage Alerts
Collapse Summary General Information
Company Affimed N.V.
DescriptionTetravalent, bispecific antibody that recruits cytotoxic NK cells to cancer cells expressing an EGFR mutation
Molecular Target Fc gamma receptor III (FCGR3) (CD16) ; Epidermal growth factor receptor (EGFR)
Mechanism of ActionBispecific antibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today